LightCycler SeptiFast technology in patients with solid
malignancies: clinical utility for rapid etiologic diagnosis of
sepsis

J 2012

LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis

DUBSKÁ, Lenka; Martina VYSKOČILOVÁ; Dagmar MINARIKOVA; Petr JELÍNEK; Renata TEJKALOVÁ et al.

Základní údaje

Originální název

LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis

Autoři

DUBSKÁ, Lenka; Martina VYSKOČILOVÁ; Dagmar MINARIKOVA; Petr JELÍNEK; Renata TEJKALOVÁ a Dalibor VALÍK

Vydání

Critical Care, LONDON, BioMed Central, 2012, 1466-609X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00062242

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1186/cc10595

UT WoS

000305393400063

Klíčová slova anglicky

SeptiFast test; bloodstream infection; microorganisms

Příznaky

Mezinárodní význam

Změněno: 23. 4. 2013 00:22, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

We retrospectively evaluated 54 results of the SeptiFast test from patients with solid malignancy admitted to the ICU between June 2009 and August 2011. Specimens from suspected bloodstream infection were analyzed using LightCycler SeptiFast (Roche Molecular Diagnostics according to the manufacturers instruction and evaluated in comparison with blood culture results obtained from blood sampled no longer than 24 hours before or after sampling for SeptiFast. Blood culturing and identification were performed according to the routine diagnostic procedures. The total number of blood cultures analyzed was 85, and finding a microorganism by either of the two tests was evaluated as positive. Consistently, negative results from SeptiFast and blood culture were obtained in 21 (39%) cases.

Přiložené soubory

download.pdf Verze souboru

Citovat

DUBSKÁ, Lenka; Martina VYSKOČILOVÁ; Dagmar MINARIKOVA; Petr JELÍNEK; Renata TEJKALOVÁ a Dalibor VALÍK. LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis. Critical Care. LONDON: BioMed Central, 2012, roč. 16, č. 1, s. "nestrankovano", 3 s. ISSN 1466-609X. Dostupné z: https://doi.org/10.1186/cc10595.

@article{1077772,
   author = {Dubská, Lenka and Vyskočilová, Martina and Minarikova, Dagmar and Jelínek, Petr and Tejkalová, Renata and Valík, Dalibor},
   article_location = {LONDON},
   article_number = {1},
   doi = {https://doi.org/10.1186/cc10595},
   keywords = {SeptiFast test; bloodstream infection; microorganisms},
   language = {eng},
   issn = {1466-609X},
   journal = {Critical Care},
   note = {Article Number: 404},
   title = {LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis},
   url = {http://ccforum.com/content/16/1/404},
   volume = {16},
   year = {2012}
}

TY  - JOUR
ID  - 1077772
AU  - Dubská, Lenka - Vyskočilová, Martina - Minarikova, Dagmar - Jelínek, Petr - Tejkalová, Renata - Valík, Dalibor
PY  - 2012
TI  - LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis
JF  - Critical Care
VL  - 16
IS  - 1
SP  - "nestrankovano"
EP  - "nestrankovano"
PB  - BioMed Central
SN  - 1466609X
N1  - Article Number: 404
KW  - SeptiFast test
KW  - bloodstream infection
KW  - microorganisms
UR  - http://ccforum.com/content/16/1/404
L2  - http://ccforum.com/content/16/1/404
N2  - We retrospectively evaluated 54 results of the SeptiFast test from patients with solid malignancy admitted to the ICU between June 2009 and August 2011. Specimens from suspected bloodstream infection were analyzed using LightCycler SeptiFast (Roche Molecular Diagnostics according to the manufacturers instruction and evaluated in comparison with blood culture results obtained from blood sampled no longer than 24 hours before or after sampling for SeptiFast. Blood culturing and identification were performed according to the routine diagnostic procedures. The total number of blood cultures analyzed was 85, and finding a microorganism by either of the two tests was evaluated as positive. Consistently, negative results from SeptiFast and blood culture were obtained in 21 (39%) cases.
ER  -

DUBSKÁ, Lenka; Martina VYSKOČILOVÁ; Dagmar MINARIKOVA; Petr JELÍNEK; Renata TEJKALOVÁ a Dalibor VALÍK. LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis. \textit{Critical Care}. LONDON: BioMed Central, 2012, roč.~16, č.~1, s.~''nestrankovano'', 3 s. ISSN~1466-609X. Dostupné z: https://doi.org/10.1186/cc10595.

Přehled o publikaci